ClinicalTrials.gov
public full text
Public Domain
Effects of GTS-21 on Smoking Behavior and Neurocognitive Functions
Attempts to quit cigarette smoking are often accompanied by negative mood and problems in attention and memory. These effects, in turn, may contribute to smoking relapse. This exploratory/developmental project examines the effects of a novel medication, GTS-21, on individuals interested in smoking cessation. It is hypothesized that GTS-21 will reduce negative affect, improve cognition and/or reduce smoking relapse in healthy adult men and women who are chronic cigarette smokers.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Smoking Cessation Program for Adults With Type 2 Diabetes Mellitus (DiMe-SALUD2 Project)#1085626
- Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking#894044
- Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study#882781
- Acute Effect of Pomegranate Extract on Cognitive Function#837139
- Cannabinoid Augmentation of Fear Response in Humans#911586
Record · ID 846113
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive